Please enable JavaScript.
Coggle requires JavaScript to display documents.
Chemotherapeutics: Mechanism of Action (Monoclonal antibody (HER2…
Chemotherapeutics: Mechanism of Action
DNA Damaging Agents
DNA binding agents
N Mustards
Mechlorethamine
Cyclophosphamide
Melphalan
Chlorambucil
Aziridines
Alkane sulphonates
Nitrosoureas
Methylating agents
Pt compounds
Cisplatin
Antibiotics
Doxorubicin
DNA Synthesis Inhibitors
Antimetabolites
Analogs
Purine
6-mercaptopurine
Cytarabine
Pyrimidine
Enxyme inhibitors
Purine
dihydrofolate reductase
methotrexate
ribonuclease diphosphotase reductase
hydroxyurea
Pr=yrimidine
thymidylate synthetase
5-fluorouracil
dihydrofolate reductase
methotrexate
ribonuclease diphosphotase reductase
hydroxyurea
Topoisomerase inhibitors
Topoisomerase I inhibitor
Irinotecan
Topoisomerase II inhibitor
Doxorubicin
Etoposide
Cytoskeleton Poison
Taxanes
Taxol
Vinca alkaloids
Vinblastine
Vincristine
Signal transduction inhibitors
BCR-ABL kinase
Imatinib
Hormone based therapy
Anti-oestrogen therapies
Aromatase inhibitors
Anastrazole
Partial agonists
Tamoxifen
Antagonists
Fulvestrant
Small molecule kinase inhibitor
EGFR
Gefitinib
BRAF
Vemurafenib
Monoclonal antibody
EGFR
Cetuximab
HER2
Trastuzumab
Pertuzamab
VEGF
Bevacizumab
CD20
rituximab
DD38
Daratumumab
SLAMF-7
Elotuzumab
Antibody drug conjugates
Brentuximab vedotin
Trastuzumab emtansine
Immunotherapies
PD-1 inhibitors
PDL-1 inhibitors